Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes.
Calcium channel blocking drugs have been reported to reduce survival rate of laboratory animals treated with cardiotoxic antitumor anthracyclines. In order to elucidate the mechanisms of this drug interaction, cell toxicity of the anthracyclines, doxorubicin and daunorubicin, was evaluated in primary cultures of cardiac myocytes isolated from neonatal rats. Low concentrations of extracellular calcium ([Ca2+]0) and addition of calcium entry blockers (nifedipine or flunarizine) potentiated myocardial toxicity of anthracyclines as assessed by the release of lactate dehydrogenase from the cells. Accumulation of anthracyclines in the cardiomyocytes was increased by calcium entry blockers (nifedipine, flunarizine, and verapamil) and by low [Ca2+]0; efflux of [3H]daunorubicin from myocardial cells was inhibited by nifedipine. At a dose that exerts only modest calcium channel activity, R-verapamil failed to affect doxorubicin accumulation in cardiomyocytes, whereas the calcium channel activator, (+/-)-Bay K-8644, reduced the retention of anthracyclines; the calcium channel activity is thus required in order to increase the accumulation of anthracyclines in myocardial cells. Calcium channel blockers are also known to increase intracellular retention and toxicity of chemotherapeutic drugs in multidrug resistant tumor cells by inhibiting the efflux of cytotoxic agents from cells; however, the ability of the interacting drugs to inhibit the efflux of chemotherapeutic agents from tumor cells is not dependent on the calcium channel blocking activity. Therefore, the mechanism(s) by which calcium channel blocking drugs increase the accumulation of anthracyclines in resistant tumor cells and myocardial cells may be different. In accordance with previous investigations, the present in vitro study confirmed that anthracycline-induced cardiotoxicity may be potentiated by calcium channel blocking drugs. This indicates that, in the association of antineoplastic drugs with agents that reverse multidrug resistance, the potential exists for enhanced damage of normal cells and tissues; further studies are needed to evaluate the relevance of this adverse interaction.
Santostasi
G
G
Section on Drug-Tissue Interaction, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.
Kutty
R K
RK
Krishna
G
G
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D002121:Calcium Channel Blockers / Q000633:toxicity*; D002478:Cells, Cultured; D003630:Daunorubicin / Q000493:pharmacokinetics; D004317:Doxorubicin / Q000493:pharmacokinetics / Q000494:pharmacology; D004351:Drug Resistance; D004357:Drug Synergism; D005444:Flunarizine / Q000494:pharmacology; D006321:Heart / Q000187:drug effects*; D009543:Nifedipine / Q000494:pharmacology; D051381:Rats
D000903:Antibiotics, Antineoplastic; D002121:Calcium Channel Blockers; D004317:Doxorubicin; D009543:Nifedipine; D005444:Flunarizine; D003630:Daunorubicin